Miriam Mengoni
Overview
Explore the profile of Miriam Mengoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Braun A, Mengoni M, Tuting T, Gaffal E
Exp Dermatol
. 2025 Feb;
34(2):e70059.
PMID: 39945026
Invasive growth and metastatic dissemination represent the primary cause of death in cancer patients. In order to successfully detach from the primary tumour and establish metastases in distant tissues, cancer...
2.
Mengoni M, Mahlo F, Gaffal E, Tuting T, Braun A
Lab Invest
. 2024 Dec;
105(3):102209.
PMID: 39675722
The success of immune checkpoint inhibitors (ICI) in melanoma therapy has catalyzed the introduction of ICI in increasingly early stages of the disease. This exposes many patients with a lower...
3.
Mengoni M, Tuting T, Gaffal E, Braun A
Oncol Ther
. 2024 Dec;
13(1):131-143.
PMID: 39661321
Introduction: The introduction of immunotherapy (IT) has transformed clinical care of patients with metastatic melanoma. However, many patients still die as a result of progressive disease. Here we analyzed how...
4.
Hansen-Abeck I, Geidel G, Abeck F, Kott J, Cankaya R, Dobos G, et al.
J Dtsch Dermatol Ges
. 2024 Oct;
22(11):1489-1497.
PMID: 39358932
Background: Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020,...
5.
Holtorf C, Mengoni M, Tuting T, Wienke A, Borggrefe J, Surov A, et al.
Dermatologie (Heidelb)
. 2024 Aug;
75(10):798-803.
PMID: 39143426
Background And Objectives: Sarcopenia is the generalized loss of muscle strength, mass, and function. The aim was to investigate whether pretherapeutic sarcopenia, as determined by the psoas muscles, affects therapy-mediated...
6.
Mengoni M, Braun A, Hinnerichs M, Aghayev A, Tuting T, Surov A
J Dtsch Dermatol Ges
. 2024 Jun;
22(6):783-791.
PMID: 38857075
Background: The introduction of tyrosine kinase inhibitors (TKI) has greatly improved the management of metastatic melanoma. Recent studies have uncovered a relationship between the body mass index (BMI) and outcome...
7.
Mengoni M, Braun A, Hinnerichs M, Aghayev A, Tuting T, Surov A
J Cancer Res Clin Oncol
. 2024 May;
150(5):275.
PMID: 38796605
Purpose: Adjuvant immunotherapy with immune checkpoint blockade(ICB) has greatly reduced the risk of recurrence and metastatic spread in early and advanced melanoma. However, not all patients benefit from adjuvant treatment:...
8.
Transactivation of Met signaling by oncogenic Gnaq drives the evolution of melanoma in Hgf-Cdk4 mice
Mengoni M, Braun A, Seedarala S, Bonifatius S, Kostenis E, Schanze D, et al.
Cancer Gene Ther
. 2024 Feb;
31(6):884-893.
PMID: 38360887
Recent pan-cancer genomic analyses have identified numerous oncogenic driver mutations that occur in a cell-type and tissue-specific distribution. For example, oncogenic mutations in Braf and Nras genes arise predominantly in...
9.
Mengoni M, Braun A, Has C, Tuting T, Gaffal E
J Dtsch Dermatol Ges
. 2023 Jul;
21(7):798-802.
PMID: 37427738
No abstract available.
10.
Mengoni M, Braun A, Hinnerichs M, Tuting T, Surov A
Acad Radiol
. 2023 Jun;
30 Suppl 1:S257-S267.
PMID: 37331867
Rationale And Objectives: Despite the impressive efficacy of immune checkpoint inhibitors (ICIs) in the treatment of metastatic melanoma, not all patients respond to therapy. In addition, ICI harbors the risk...